Neocortical volume decrease in relapsing–remitting MS patients with mild cognitive impairment
Abstract
Objective: To assess neocortical changes and their relevance to cognitive impairment in early relapsing–remitting (RR) multiple sclerosis (MS).
Methods: Conventional MR was acquired in 41 patients with RR MS and 16 demographically matched normal control subjects (NCs). An automated analysis tool was used with conventional T1-weighted MRI to obtain measures of cortical brain volumes normalized for head size. Neuropsychological performance of MS patients was assessed using the Rao Brief Repeatable Battery. Relationship between volumetric MR measures and neuropsychological scores was assessed.
Results: Neuropsychological assessment allowed for the identification of 18 cognitively preserved (MS-cp) and 23 cognitively impaired (MS-ci) MS patients. The whole MS sample showed lower values of normalized cortical volumes (NCVs) than did the NC group (p = 0.01). Upon grouping of MS patients according to cognitive performance, NCV values were lower (p = 0.02) in MS-ci patients than in both MS-cp patients and NCs. Moreover, there were positive correlations between NCV values and measures of verbal memory (r = 0.51, p = 0.02), verbal fluency (r = 0.51, p = 0.01), and attention/concentration (r = 0.65, p < 0.001) in MS-ci patients. Furthermore, NCV values were decreased in patients who scored lower on a greater number of tests (r = −0.58, p < 0.01) in the MS-ci group. None of the neuropsychological measures correlated to NCV values in the MS-cp patient group.
Conclusions: Cortical atrophy was found only in cognitively impaired patients and was significantly correlated with a poorer performance on tests of verbal memory, attention/concentration, and verbal fluency. Gray matter pathology may contribute to the development of cognitive impairment in MS from the earliest stages of the disease.
Get full access to this article
View all available purchase options and get full access to this article.
References
1.
Miller DH, Barkhof F, Frank JA, Parker GJ, Thompson AJ. Measurement of atrophy in multiple sclerosis: pathological basis, methodological aspects and clinical relevance. Brain. 2002; 1676–1695.
2.
Losseff NA, Wang L, Lai HM, et al. Progressive cerebral atrophy in multiple sclerosis. A serial MRI study. Brain. 1996; 119: 2009–2019.
3.
Rudick RA, Fisher E, Lee JC, Simon J, Jacobs L. Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing–remitting MS. Multiple Sclerosis Collaborative Research Group. Neurology. 1999; 53: 1698–1704.
4.
Fox NC, Jenkins R, Leary SM, et al. Progressive cerebral atrophy in MS: a serial study using registered, volumetric MRI. Neurology. 2000; 54: 807–812.
5.
Smith SM, Zhang Y, Jenkinson M, et al. Accurate, robust and automated longitudinal and cross-sectional brain change analysis. Neuroimage. 2002; 17: 479–489.
6.
Stevenson VL, Smith SM, Matthews PM, Miller DH, Thompson AJ. Monitoring disease activity and progression in primary progressive multiple sclerosis using MRI: sub-voxel registration to identify lesion changes and to detect cerebral atrophy. J Neurol. 2002; 249: 171–177.
7.
Rovaris M, Comi G, Rocca MA, Wolinsky JS, Filippi M. Short-term brain volume change in relapsing–remitting multiple sclerosis: effect of glatiramer acetate and implications. Brain. 2001; 124: 1803–1812.
8.
Peterson JW, Bo L, Mork S, Chang A, Trapp BD. Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions. Ann Neurol. 2000; 50: 389–400.
9.
Cifelli A, Arridge M, Jezzard P, Esiri MM, Palace J, Matthews PM. Thalamic neurodegeneration in multiple sclerosis. Ann Neurol. 2002; 52: 650–653.
10.
De Stefano N, Matthews PM, Filippi M, et al. Evidence of early cortical atrophy in MS: relevance to white matter changes and disability. Neurology. 2003; 60: 1157–1162.
11.
Chard DT, GrifÆn CM, Parker GJM, Kapoor R, Thompson AJ, Miller DH. Brain atrophy in clinically early relapsing–remitting multiple sclerosis. Brain. 2002; 125: 327–337.
12.
Sailer M, Fischl B, Salat D, et al. Focal thinning of the cerebral cortex in multiple sclerosis. Brain. 2003; 126: 1734–1744.
13.
Wylezinska M, Cifelli A, Jezzard P, Palace J, Alecci M, Matthews PM. Thalamic neurodegeneration in relapsing–remitting multiple sclerosis. Neurology. 2003; 60: 1949–1954.
14.
Rao SM. Neuropsychological aspects of multiple sclerosis. In: Raine CS, McFarland HF, Tourtellotte WW, eds. Multiple sclerosis: clinical and pathogenetic basis. London: Chapman & Hall, 1997: 357–362.
15.
Amato MP, Ponziani G, Pracucci G, et al. Cognitive impairment in early-onset multiple sclerosis: pattern, predictors, and impact on everyday life in a 4-year follow-up. Arch Neurol. 1995; 52: 168–172.
16.
Amato MP, Ponziani G, Siracusa G, Sorbi S. Cognitive dysfunction in early-onset multiple sclerosis. A reappraisal after 10 years. Arch Neurol. 2001; 58: 1602–1606.
17.
Rao SM, Leo GJ, Haughton VM, Aubin-Faubert P, Bernardin L. Correlation of magnetic resonance imaging with neuropsychological testing in multiple sclerosis. Neurology. 1989; 39: 161–166.
18.
Rovaris M, Filippi M, Falautano M, et al. Relation between MR abnormalities and patterns of cognitive impairment in multiple sclerosis. Neurology. 1998; 50: 1601–1608.
19.
Lazeron RH, Langdon DW, Filippi M, et al. Neuropsychological impairment in multiple sclerosis patients: the role of (juxta)cortical lesion on FLAIR. Mult Scler. 2000; 6: 280–285.
20.
Rao SM, Glatt S, Hammeke TA, et al. Chronic progressive multiple sclerosis. Relationship between cerebral ventricular size and neuropsychological impairment. Arch Neurol. 1985; 42: 678–682.
21.
Franklin GM, Heaton RK, Nelson LM, Filley CM, Seibert C. Correlation of neuropsychological and MRI findings in chronic/progressive multiple sclerosis. Neurology. 1988; 38: 1826–1829.
22.
Huber SJ, Bornstein RA, Rammohan KW, Christy JA, Chakeres DW, McGhee RB. Magnetic resonance imaging correlates of neuropsychological impairment in multiple sclerosis. J Neuropsychiatry Clin Neurosci. 1992; 4: 152–158.
23.
Filippi M, Tortorella C, Rovaris M, et al. Changes in the normal appearing brain tissue and cognitive impairment in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2000; 68: 157–161.
24.
Trapp BD, Bo L, Mork S, Chang A. Pathogenesis of tissue injury in MS lesions. J Neuroimmunol. 1999; 98: 49–56.
25.
Rao SM, Bernardin L, Leo GJ, Ellington L, Ryan SB, Burg LS. Cerebral disconnection in multiple sclerosis. Relationship to atrophy of the corpus callosum. Arch Neurol. 1989; 46: 918–920.
26.
Christodoulou C, Krupp LB, Liang Z, et al. Cognitive performance and MR markers of cerebral injury in cognitively impaired MS patients. Neurology. 2003; 60: 1793–1798.
27.
Hohol MJ, Guttmann CR, Orav J, et al. Serial neuropsychological assessment and magnetic resonance imaging analysis in multiple sclerosis. Arch Neurol. 1997; 54: 1018–1025.
28.
Zivadinov R, Sepcic J, Nasuelli D, et al. A longitudinal study of brain atrophy and cognitive disturbances in the early phase of relapsing–remitting multiple sclerosis. J Neurol Neurosurg Psychiatry. 2001; 70: 773–780.
29.
Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol. 1983; 13: 227–231.
30.
Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an Expanded Disability Status Scale (EDSS). Neurology. 1983; 33: 1444–1452.
31.
Rao SM and the Cognitive Function Study Group of the National Multiple Sclerosis Society. A manual for the Brief Repeatable Battery of Neuropsychological Tests in Multiple Sclerosis. Medical College of Wisconsin, Milwaukee, WI 1990.
32.
Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979; 134: 382–389.
33.
Boringa JB, Lazeron RH, Reuling IE, et al. The Brief Repeatable Battery of Neuropsychological Tests: normative values allow application in multiple sclerosis clinical practice. Mult Scler. 2001; 7: 263–267.
34.
Smith SM, De Stefano N, Jenkinson M, Matthews PM. Normalized accurate measurement of longitudinal brain change. J Comput Assist Tomogr. 2001; 25: 466–475.
35.
Zhang Y, Brady M, Smith S. Segmentation of brain MR images through a hidden Markov random field model and the expectation maximization algorithm. IEEE Trans Biomed Imag. 2001; 20: 45–57.
36.
Mittmann N, Mitter S, Borden EK, Herrmann N, Naranjo CA, Shear NH. Montgomery–Asberg severity gradations. Am J Psychiatry. 1997; 154: 1320–1321.
37.
Blinkenberg M, Rune K, Jensen CV, et al. Cortical cerebral metabolism correlates with MRI lesion load and cognitive dysfunction in MS. Neurology. 2000; 54: 558–564.
38.
Greenaeld JG, King LS. Observations on the histopathology of the cerebral lesions in disseminated sclerosis. Brain. 1936; 59: 445–458.
39.
Sperling RA, Guttmann CR, Hohol MJ, et al. Regional magnetic resonance imaging lesion burden and cognitive function in multiple sclerosis: a longitudinal study. Arch Neurol. 2001; 58: 115–121.
40.
Narayanan S, Fu L, Pioro E, et al. Imaging of axonal damage in multiple sclerosis: spatial distribution of magnetic resonance imaging lesions. Ann Neurol. 1997; 41: 385–391.
41.
Evangelou N, Konz D, Esiri MM, Smith S, Palace J, Matthews PM. Size-selective neuronal changes in the anterior optic pathways suggest a differential susceptibility to injury in multiple sclerosis. Brain. 2001; 124: 1813–1820.
42.
Lumsden CE. The neuropathology of multiple sclerosis. In: PJVinken GWBruyn eds. Handbook of clinical neurology. Amsterdam: North Holland, 1970: 296–298.
43.
Kidd D, Barkhof F, McConnell R, Algra PR, Allen IV, Revesz T. Cortical lesions in multiple sclerosis. Brain. 1999; 122: 17–26.
44.
Bitsch A, Schuchardt J, Bunkowski S, Kuhlmann T, Bruck W. Acute axonal injury in multiple sclerosis. Correlation with demyelination and inflammation. Brain. 2000; 123: 1174–1183.
45.
Garbern JY, Yool DA, Moore GJ, et al. Patients lacking the major CNS myelin protein, proteolipid protein 1, develop length-dependent axonal degeneration in the absence of demyelination and inflammation. Brain. 2002; 125: 551–561.
Information & Authors
Information
Published In
Copyright
© 2004.
Publication History
Received: October 1, 2003
Accepted: February 27, 2004
Published online: July 12, 2004
Published in print: July 13, 2004
Authors
Metrics & Citations
Metrics
Citation information is sourced from Crossref Cited-by service.
Citations
Download Citations
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.
Cited By
- Cognition in multiple sclerosis, Handbook of Imaging in Multiple Sclerosis, (51-70), (2025).https://doi.org/10.1016/B978-0-323-95739-7.00018-6
- The contribution of tumor necrosis factor to multiple sclerosis: a possible role in progression independent of relapse?, Journal of Neuroinflammation, 21, 1, (2024).https://doi.org/10.1186/s12974-024-03193-6
- Cognitive rehabilitation effects on grey matter volume and Go-NoGo activity in progressive multiple sclerosis: results from the CogEx trial, Journal of Neurology, Neurosurgery & Psychiatry, 95, 12, (1139-1149), (2024).https://doi.org/10.1136/jnnp-2024-333460
- Multiple sclerosis, The Rose and Mackay Textbook of Autoimmune Diseases, (1457-1487), (2024).https://doi.org/10.1016/B978-0-443-23947-2.00061-8
- The Prevalence of Cognitive Impairment in Relapsing-Remitting Multiple Sclerosis: A Systematic Review and Meta-analysis, Neuropsychology Review, (2024).https://doi.org/10.1007/s11065-024-09640-8
- The contribution of paramagnetic rim and cortical lesions to physical and cognitive disability at multiple sclerosis clinical onset: evaluating the power of MRI and OCT biomarkers, Journal of Neurology, 271, 10, (6702-6714), (2024).https://doi.org/10.1007/s00415-024-12622-8
- Evaluation of the correlation between thalamic area and cognitive functions in patients with early-stage relapsing-remitting multiple sclerosisErken Evre Relapsing-Remitting Multipl Skleroz Hastalarında Talamus Alanı ile Bilişsel İşlevler Arasındaki İlişkinin Değerlendirilmesi, Cukurova Anestezi ve Cerrahi Bilimler Dergisi, 6, 2, (280-289), (2023).https://doi.org/10.36516/jocass.1333415
- Current Status of Oral Disease-Modifying Treatment Effects on Cognitive Outcomes in Multiple Sclerosis: A Scoping Review, Bioengineering, 10, 7, (848), (2023).https://doi.org/10.3390/bioengineering10070848
- Neuropsychiatric Manifestations of Multiple Sclerosis and the Effects of Modern Disease-Modifying Therapies, Advances in Psychiatry and Behavioral Health, 3, 1, (239-253), (2023).https://doi.org/10.1016/j.ypsc.2023.04.001
- Effect of deep gray matter atrophy on information processing speed in early relapsing-remitting multiple sclerosis, Multiple Sclerosis and Related Disorders, 71, (104560), (2023).https://doi.org/10.1016/j.msard.2023.104560
- See more
Loading...
View Options
Login options
Check if you have access through your login credentials or your institution to get full access on this article.
Personal login Institutional LoginPurchase Options
The neurology.org payment platform is currently offline. Our technical team is working as quickly as possible to restore service.
If you need immediate support or to place an order, please call or email customer service:
- 1-800-638-3030 for U.S. customers - 8:30 - 7 pm ET (M-F)
- 1-301-223-2300 for customers outside the U.S. - 8:30 - 7 pm ET (M-F)
- [email protected]
We appreciate your patience during this time and apologize for any inconvenience.